ProQR Therapeutics N.V.
PRQR
$1.76
-$0.06-3.30%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -12.33% | -12.02% | 7.57% | 82.27% | 190.22% |
| Total Other Revenue | -30.10% | 8.93% | 79.24% | 159.17% | 701.62% |
| Total Revenue | -12.91% | -11.45% | 9.23% | 84.08% | 196.41% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -12.91% | -11.45% | 9.23% | 84.08% | 196.41% |
| SG&A Expenses | 15.40% | 6.19% | 5.97% | -15.04% | -15.84% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 24.71% | 28.46% | 34.85% | 18.64% | 20.92% |
| Operating Income | -48.82% | -53.21% | -49.11% | 1.98% | 12.33% |
| Income Before Tax | -57.52% | -79.90% | -85.87% | -12.71% | -0.63% |
| Income Tax Expenses | 110.19% | 109.87% | 108.12% | -163.85% | -149.71% |
| Earnings from Continuing Operations | -58.70% | -81.40% | -87.99% | -12.29% | -0.21% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -58.70% | -81.40% | -85.44% | -11.00% | 1.17% |
| EBIT | -48.82% | -53.21% | -49.11% | 1.98% | 12.33% |
| EBITDA | -52.79% | -57.46% | -53.02% | 2.69% | 14.18% |
| EPS Basic | -30.70% | -42.17% | -53.70% | 3.82% | 7.73% |
| Normalized Basic EPS | -29.67% | -25.82% | -25.74% | 17.31% | 21.26% |
| EPS Diluted | -33.13% | -44.78% | -57.29% | 2.69% | 7.83% |
| Normalized Diluted EPS | -29.67% | -25.82% | -25.74% | 17.31% | 21.26% |
| Average Basic Shares Outstanding | 22.36% | 27.37% | 20.37% | 13.35% | 6.27% |
| Average Diluted Shares Outstanding | 22.36% | 27.37% | 20.37% | 13.35% | 6.27% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |